Novasign Studio for biopharma process development
Start with one product. Build a workflow. Apply it across your portfolio. Turn your organization’s process knowledge into reusable workflows. Fewer experiments, faster decisions, and scale-up confidence built on what you already have.
The overhead that holds biopharma process teams back
The challenge is rarely a shortage of data, models or expertise. It is that none of them are structured to be reused across programs, teams or development stages, so rebuilding what already exists has become part of the job.
Historical knowledge stays locked in the past
Process data exists across campaigns, products and development stages, but consolidating it into a usable form takes real effort. When finding and extracting past data feels open-ended, running a new experiment becomes the path of least resistance. Knowledge gets rebuilt not by choice, but because reusing it reliably is harder than it should be.
In-house digital tools rarely scale beyond the person who built them
Internal models, code snippets and analytical pipelines often work well for their author. Making that capability available to the broader team, across molecules and sites, is where it consistently stalls.
Process teams have to become advocates for a tool, not just users of it
When a workflow does not fit how process teams actually work, even technically strong solutions fail to gain traction. People need to see clear value in their daily work before they will defend a digital tool.
Scale-up confidence gaps create expensive late-stage risk
Process understanding built at lab scale does not always hold at pilot or manufacturing scale. When that gap surfaces late, the consequences are concrete: delayed programs, failed batches, and unplanned engineering campaigns that could have been avoided earlier.
Build-versus-buy inertia slows digital progress
Data processing, model validation and maintenance, a usable interface for process teams, and adoption each become a separate project. In the meantime, teams develop workarounds that get the job done.
One connected workflow, from process data to well-justified decisions
Novasign Studio introduces a structured workflow layer across your development process and gives each step a structured home, open to extension where you need it. It does not replace your existing models, scripts or data infrastructure, it makes them reusable, reproducible and shareable across your organization. Each step is designed to fit how process teams already work rather than to require a new way of working.
1 · Plan
Design smarter experiments around the specific decision you need to make, from screening and process optimization with model-based design of experiments to intensified DoE for process characterization.
Where Novasign Studio fits in biopharma process development
One platform for all unit operations, upstream to downstream, from early-stage feasibility through technology transfer and process handoff.
Historical data proof of concept
The most common starting point is building a process model from data your team already has, such as campaign data from prior development runs, without generating a single new experiment. That lets your team evaluate what Novasign Studio produces in your specific context, with your own data, before any further commitment. The output is a working model and a clear view of which questions it can and cannot answer at this stage.
How a study startsUpstream process optimization
Model-based design of experiments for batch, fed-batch and perfusion processes, including seed trains. Rather than screening a predefined set of conditions, Novasign Studio builds a model from your existing data and identifies which untested combinations of process conditions are most likely to contain the optimum. Experimental effort goes to the runs most likely to be informative instead of being spread across a predefined grid.
Process characterization
Once the objectives are defined, the focus shifts to the design space: which critical process parameters drive variability in critical quality attributes, and within which ranges does the process stay in specification? Model-based characterization identifies CPP to CQA linkage with fewer runs than standard design of experiments, and gives the characterization package a stronger basis.
Downstream development and robustness
Filtration workflows including tangential-flow filtration in ultrafiltration and diafiltration mode, on a dedicated process unit. Chromatography workflows covering batch bind-elute and flow-through formats as well as continuous chromatography. Across all of them, model-based optimization and characterization establish robust operating windows with fewer runs.
Scale-up and technology transfer prediction
Scenario-based simulation lets the model predict large-scale performance before engineering or manufacturing runs happen, so those runs validate expectations rather than explore them. Where bioreactor geometry matters, CFD-derived parameters such as kLa, mixing time, shear rate and power per volume (P/V), from Novasign’s technology partner SimVantage, are integrated directly into the process model, which puts a quantified basis under the prediction. Process understanding is built to apply across scales, from lab through pilot to manufacturing.
How Arkeon scaled up from 2 L to 150 LDeviation investigation support
When a deviation occurs, the first problem is having enough traceable information to understand what happened and why. Reproducible data processing workflows mean every transformation step is documented and repeatable, so process and quality teams see not only the data but how conclusions were drawn, which process parameters were considered, and how the process was characterized at the time. Studio supports the scientific investigation behind a deviation; the CAPA record stays in your quality system.
Cross-project workflow standardization
Process knowledge built for one molecule does not have to stay with that molecule. Novasign Studio captures the experimental planning logic, the data processing steps and the model structure behind a process decision in a reusable workflow. The next program starts from an established baseline rather than from scratch, and the knowledge belongs to the team rather than to whoever developed it the first time.
Does this sound like your team?
Three kinds of situation tend to bring people to Novasign Studio. If one of them describes a problem your team has, this page is for you.
- For VPs of process development, heads of bioprocess sciences and CMC directors
Your team keeps redoing work it has already done.
You have historical data, internal expertise, and development campaigns that produced real process knowledge. The problem is that the knowledge is not reusable: it lives in files, in tools, and in the heads of the people who built it. Without a structured way to capture it, it stays personal rather than shared, and the next team starts from scratch instead of building on what exists.
- For digital CMC leads, process modelling leads and data science leads
Your team has models and scripts that only one person can use.
Your team has invested real effort in digital capability: data processing scripts, analytical pipelines, models. The people who built them want that work to be useful to the broader team rather than locked to their own desk. Novasign gives it a structured home, so process teams apply it directly without needing the original author to explain, translate, or be in the room.
- For process scientists, research scientists and USP or DSP process engineers
You need a modelling workflow you can run yourself.
You know the biology and you know which questions need answering. What you need is a workflow you can drive yourself, without waiting for a data scientist to be available or asking them to rerun the analysis every time something changes. Novasign Studio gives you a no-code interface for day-to-day process work, with the models and scripts your colleagues built already integrated and ready to use.
Why biopharma teams choose Novasign Studio
Reuse what your organization already knows
Historical process data from prior campaigns, development runs and platform molecules already exists inside your organization. Novasign makes it usable for the next decision instead of designing another experiment to rediscover it.
Bring your own models, scripts and code
Novasign does not replace internal models or custom scripts that already work. Your existing digital assets integrate directly as shared, reusable workflows the broader team can use.
Designed for process team adoption
A no-code interface where process teams need speed, code-ready where data scientists need flexibility, and transparent model logic every stakeholder can follow. Built so the workflow gains traction across the team rather than merely being deployed.
Upstream to downstream in one workflow
The bioreactor, tangential-flow filtration (TFF) and chromatography each have a dedicated unit in Novasign Studio. Scale-up and technology transfer run in the same workflow, not in disconnected tools. Understanding from one step informs decisions in the next.
Start with a scoped proof of concept and expand
Start with one process question and your existing data. Novasign reviews the scope, delivers a clear proposal, and demonstrates value before any license decision is required. Every successful collaboration we have had with a biopharma team started this way.
How Novasign Studio compares
Build on what you already have. Your organization has valuable code, models, datasets and scientific expertise. The challenge is not a lack of digital capability, it is making that capability usable, reproducible and accessible beyond the person who created it. Novasign Studio is designed to accelerate and scale what you are already building.
| Internal build or existing tools | Novasign Studio | |
|---|---|---|
| Time to value | Months to years. Data processing, model building, user interface and adoption are each a separate project. | Weeks to a first feasibility result. The workflow infrastructure is pre-built and data processing is included. |
| Process team adoption | High risk. Tools built by data scientists often need data scientists to run them, so process teams stay dependent on whoever built the tool. | Designed for process teams. No-code interface, transparent models, built for daily use without specialist support. |
| Your existing code and models | You own them, but they are accessible only to the expert who built them. | Integrate your scripts and models directly, in a reusable format available to the whole team. |
| Maintenance overhead | Ongoing. Every new dataset, modality or site becomes a separate IT project. | Maintained by Novasign, with regular updates and on-premises or cloud deployment. |
| Traceable process decisions | Often transparent internally, but hard to document reproducibly for a regulatory dossier. | Traceable inputs, documented datasets, workflow logic and model configuration, reproducible outputs your team can stand behind. |
| Entry cost and risk | High total cost of ownership. Talent, maintenance and adoption often exceed estimates. | Scoped feasibility first, no large upfront commitment, scale once value is proven. |
Time to value
- Internal build or existing tools
- Months to years. Data processing, model building, user interface and adoption are each a separate project.
- Novasign Studio
- Weeks to a first feasibility result. The workflow infrastructure is pre-built and data processing is included.
Process team adoption
- Internal build or existing tools
- High risk. Tools built by data scientists often need data scientists to run them, so process teams stay dependent on whoever built the tool.
- Novasign Studio
- Designed for process teams. No-code interface, transparent models, built for daily use without specialist support.
Your existing code and models
- Internal build or existing tools
- You own them, but they are accessible only to the expert who built them.
- Novasign Studio
- Integrate your scripts and models directly, in a reusable format available to the whole team.
Maintenance overhead
- Internal build or existing tools
- Ongoing. Every new dataset, modality or site becomes a separate IT project.
- Novasign Studio
- Maintained by Novasign, with regular updates and on-premises or cloud deployment.
Traceable process decisions
- Internal build or existing tools
- Often transparent internally, but hard to document reproducibly for a regulatory dossier.
- Novasign Studio
- Traceable inputs, documented datasets, workflow logic and model configuration, reproducible outputs your team can stand behind.
Entry cost and risk
- Internal build or existing tools
- High total cost of ownership. Talent, maintenance and adoption often exceed estimates.
- Novasign Studio
- Scoped feasibility first, no large upfront commitment, scale once value is proven.
Start with one process question. See what your data can do.
The right starting point if you want concrete results. We work with you on a scoped proof of concept using your existing process data, so the outcome is relevant to your specific context from the first step.
- 1
Scoping call
We sign an NDA with you. Then you define one process challenge and one unit operation or workflow to focus on.
- 2
Data review
Novasign reviews your existing data and defines what the proof of concept can produce, at no cost up to this point.
- 3
Proof of concept
We build and run the workflow in Novasign Studio together with you.
- 4
Results
Clear outputs, a defined scope, and your decision on how to proceed.
- 5
Handover
The project is handed over to you in Novasign Studio, so your team continues from where the proof of concept ended.
Relevant case studies
- 8 runs instead of 22in a process optimization campaignBespark*bio
Bespark*bio, a contract research and development organization, built a model on a reduced campaign (8 runs instead of 22) that predicted its client’s viral-vector process as well as a model built on the full campaign.
- 5experiments to design a biosimilar CQA processRepligen
Five experiments were enough to map a design space for a biosimilar monoclonal antibody, the region where glycosylation and glycation both meet their limits at once.
- 60%higher upstream titer, and a continuous process run end to endECONTI consortium
Intensified DoE raised the upstream titer 60% over the original process conditions, model predictions guided the chromatography switching, and the estimated production cost fell to €8,465 per kg against €12,382 for fed-batch.
Questions biopharma teams ask first
What you need to get started, how many experiments it takes, whether a data science team is required, whether to begin with a proof of concept or go straight to a license, and how deployment, transparency and model ownership work, are all answered in the frequently asked questions.
Build digital capability, one workflow at a time
Start with one process question that matters to your team. Deliver a clear result, build confidence, and expand from there.